University of Pittsburgh
Active, not recruiting
For more information, see ClinicalTrials.gov NCT02842203
This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).
Stage III Colorectal Cancer
Robert Schoen, MD